Phase 2 study of Lu-177-DOTATATE in inoperable paraganglioma - pheochromocytoa

Division Of Basic Sciences - Nci

Investigators

Linked publications & trials

Abstract

The goal of this project it to assess the safety and to evaluate the ability of Lu-177-DOTATATE to improve upon progression-free survival (PFS) at 6 months in patients with inoperable, SSTR positive PHEO/PGL by comparing PFS of patients treated with Lu-177-DOTATATE to historical controls from existing literature. This will be an early phase clinical trial of 90 patients which will seek to determine whether Lu-177-DOTATATE can be used to improved the PFS in the rare tumor metastatic pheochromocytoma and paraganglioma. This is a collaborative project with Dr. Karel Pacak of NICHD.